Cephalosporin antibiotics are commonly used but can result in allergic reactions and anaphylaxis. There is no clear diagnostic approach for cephalosporin-allergic patients, and guidance for the use of other antibiotics in allergic patients is based on side chain chemical similarity and limited skin testing evidence. This project includes a clinical trial and mechanistic studies to optimize the approach to cephalosporin allergy and advance future diagnostics.

Start Date01 Aug 2024

Sponsor / Collaborator

The General Hospital Corp.

[+1]

NCT05977868 / Enrolling by invitationPhase 4IIT

Comparing Oral Versus Parenteral Antimicrobial Therapy (COPAT) Trial

This is an investigator initiated multisite pragmatic randomized controlled trial designed to demonstrate equivalent effectiveness with improved safety of early transition from intravenous (IV) antimicrobial therapy to complex outpatient oral antimicrobial therapy (COpAT) across various infectious diseases (endovascular, bone and joint, skin and soft tissue, pulmonary, gastrointestinal, and genitourinary infections).
All patients referred for outpatient parenteral antimicrobial therapy (OPAT) will be evaluated by the research team with respect to inclusion/exclusion criteria. If determined eligible for enrollment, patients will be approached by a study investigator who will present the COPAT Trial. Once informed consent is obtained, patients will be randomized 2:1 using computer software into experimental or control (standard of care) group, respectively: Experimental: COpAT only on hospital discharge; Control: Conventional OPAT, OPAT transitioned to COpAT later in outpatient setting, or long-acting parenteral lipoglycopeptides. Both groups will be followed by an ID physician on the research team with in-person or telemedicine ID Clinic standard of care visits at 2, 6, and 12 weeks after hospital discharge. At the 6-week ID Clinic follow-up, patients will be asked to complete a patient satisfaction survey. The following 2 primary outcomes will be assessed: cure at 3 months using clinical (resolution of infection) and laboratory parameters (improvement in inflammatory markers) and adverse events related to antimicrobial therapy/vascular access complication. The following 3 secondary outcomes will be assessed: overall readmission at 3 months, readmission related to initial infection or antimicrobial therapy/vascular access complication at 3 months, and patient satisfaction at 6 weeks. The experimental group is being compared to standard of care in current clinical practice.
As this is a pragmatic clinical trial, patients will not undergo additional invasive testing or procedures.

Start Date04 Aug 2023

Sponsor / Collaborator

West Virginia University

CTR20223214 / CompletedNot Applicable

中国健康受试者空腹和餐后单次口服头孢羟氨苄片的随机、开放、两序列、两周期、双交叉设计的生物等效性试验

[Translation] A randomized, open-label, two-sequence, two-period, double-crossover bioequivalence study of a single oral dose of cefadroxil tablets in Chinese healthy volunteers on an empty stomach or after a meal

主要目的： 1.研究空腹单次口服头孢羟氨苄片受试制剂（1.0g，海南广升誉制药有限公司提供）与头孢羟氨苄片参比制剂（1000mg，持证商：TEVA PHARMACEUTICALS USA）后头孢羟氨苄在中国健康受试者体内的药代动力学行为，评价空腹口服两种制剂的生物等效性。 2.研究餐后单次口服头孢羟氨苄片受试制剂（1.0g，海南广升誉制药有限公司提供）与头孢羟氨苄片参比制剂（1000mg，持证商：TEVA PHARMACEUTICALS USA）后头孢羟氨苄在中国健康受试者体内的药代动力学行为，评价餐后口服两种制剂的生物等效性。次要目的：评价中国健康受试者空腹和餐后单次口服头孢羟氨苄片受试制剂和参比制剂后的安全性。

[Translation]

Main objectives: 1. To study the pharmacokinetic behavior of cefadroxil in healthy Chinese subjects after a single oral administration of the test formulation of cefadroxil tablets (1.0g, provided by Hainan Guangshengyu Pharmaceutical Co., Ltd.) and the reference formulation of cefadroxil tablets (1000mg, licensee: TEVA PHARMACEUTICALS USA) on an empty stomach, and to evaluate the bioequivalence of the two formulations after oral administration on an empty stomach. 2. To study the pharmacokinetic behavior of cefadroxil in healthy Chinese subjects after a single oral administration of the test formulation of cefadroxil tablets (1.0g, provided by Hainan Guangshengyu Pharmaceutical Co., Ltd.) and the reference formulation of cefadroxil tablets (1000mg, licensee: TEVA PHARMACEUTICALS USA) after a meal, and to evaluate the bioequivalence of the two formulations after oral administration on a empty stomach. Secondary objectives: To evaluate the safety of the test formulation and reference formulation of cefadroxil tablets in healthy Chinese subjects after a single oral administration on an empty stomach and after a meal.

Start Date04 Feb 2023

Sponsor / Collaborator

Hainan Guangshengyu Pharmaceutical Co., Ltd.

100 Clinical Results associated with Cefadroxil

100 Translational Medicine associated with Cefadroxil

100 Patents (Medical) associated with Cefadroxil

883

Literatures (Medical) associated with Cefadroxil

07 Jan 2024·Japanese journal of clinical oncology

Clinical characterization of patients with gBRCA1/2 mutation-positive unresectable pancreatic cancer: a multicenter prospective study

Article

Author: Nagashima, Hiroyuki ; Shibata, Takanori ; Sakurai, Akihiro ; Murota, Ayako ; Arihara, Yohei ; Ishikawa, Kazuma ; Kasahara, Kaoru ; Ono, Michihiro ; Kubo, Tomohiro ; Muramatsu, Joji ; Takada, Kohichi ; Yoshida, Makoto ; Tamura, Fumito ; Usami, Makoto ; Ikeda, Yuki ; Nakamura, Hajime ; Watanabe, Daichi

Abstract:

Background:

Accumulating evidence has demonstrated platinum-based chemotherapy followed by maintenance therapy with a poly Adenosine diphosphate (ADP)-ribose polymerase inhibitor (olaparib) show benefits in unresectable pancreatic cancer with a germline (g)BRCA1/2 mutation. Evaluation of the germline BRCA1 and BRCA2 mutation is essential for making decisions on a treatment strategy for patients with unresectable pancreatic cancer. However, the detection rates of germline BRCA1 and BRCA2 mutations and efficacy of maintenance with olaparib remain undetermined, prospectively, in Japan.

Methods & Results:

In this prospective analysis, the rate of germline BRCA1 and BRCA2 mutations and efficacy of chemotherapy were analyzed in 136 patients with pancreatic cancer who underwent BRACAnalysis® (85 patients) or FoundationOne® CDx (51 patients) between January 2020 and July 2022. A total of six patients (4.4%) had a germline BRCA1 and BRCA2 mutation. Five patients were treated with modified FOLFIRINOX and one with fluorouracil and oxaliplatin. All patients continued platinum-based chemotherapy for ˃4 months and were subsequently treated with olaparib as a maintenance therapy. The response rate to platinum-based chemotherapy in the germline BRCA1 and BRCA2 mutation-positive group was significantly better than that of the germline BRCA1 and BRCA2 mutation-negative group (66% vs 23%, P = 0.04). All patients harbouring a germline BRCA1 and BRCA2 mutation were able to switch to olaparib. The median progression-free survival using olaparib was 5.7 months (range 3.0–9.2).

Conclusions:

The rate of germline BRCA1 and BRCA2 mutations found in patients with unresectable pancreatic cancer was comparable to those of previous studies.An analysis of germline BRCA1 and BRCA2 mutations has benefits for all patients with unresectable pancreatic cancer with regard to decisions on therapeutic strategies in a clinical practice setting.

01 Dec 2023·Chinese clinical oncology

Twenty-five years with companion diagnostics

Article

Author: Jørgensen, Jan Trøst

For decades, pharmacotherapy has been hampered by significant patient variability, and the inability to predict outcomes at the individual patient level has negatively affected its value. However, progress in molecular medicine has led to an increased understanding of the pathophysiology and mechanisms of action of drugs, thereby enabling the development of predictive biomarkers. Companion diagnostics (CDx) belongs to the group of predictive biomarkers, which the Food and Drug Administration (FDA) defines as an in vitro diagnostic device that provides information that is essential for the safe and effective use of a corresponding therapeutic product. In September 1998, 25 years ago, the FDA approved the first CDx assay, the HercepTest, an immunohistochemical (IHC) assay for the detection of HER2 protein expression. This assay is linked to the use of the monoclonal antibody trastuzumab in the treatment of HER2 positive breast cancer. The HercepTest is not the only CDx developed. Currently, more than 60 drugs or drug combinations, primarily in hematology and oncology, have been approved by the FDA, with CDx assays linked to their use. The current article briefly discusses the subject of CDx and provides an overview of its evolution over the past 25 years, with particular emphasis on the United States.

01 Dec 2023·Open forum infectious diseases

First-Generation Cephalosporins for Treatment of Acute Hematogenous Osteomyelitis in Children: A Study of Efficacy and Adverse Effects

Article

Author: Ristagno, Elizabeth H ; Levy, Emily R ; Hiskey, Lisa ; Saifuddin, Hiba ; Dinnes, Laura M ; Hentz, Roland ; Rajapakse, Nipunie S

Abstract:

Background:

Acute hematogenous osteomyelitis (AHO) is a relatively infrequent but significant infection in pediatric patients. As Staphylococcus aureus is the most common cause of AHO, intravenous and oral first-generation cephalosporins are common therapies. Cephalexin is a commonly prescribed oral therapy for pediatric AHO, although it requires frequent dosing that may affect adherence. Cefadroxil is a comparable oral first-generation cephalosporin with a more desirable dosing schedule.

Methods:

We reviewed pediatric patients admitted to Mayo Clinic between March 2002 and September 2020 for management of AHO who received treatment with a first-generation cephalosporin. We reviewed timing of oral therapy transition, therapy-associated adverse effects, and recurrence of disease after completion of therapy.

Results:

There were 59 patients included in the study. There was similar occurrence of adverse effects in patients receiving cefadroxil and cephalexin, although use of cefadroxil coincided with more gastrointestinal adverse effects and leukopenia and use of cephalexin with more rash and neutropenia. One secondary treatment failure occurred in our study, in a patient receiving cephalexin for treatment of septic arthritis.

Conclusions:

Cefadroxil may be a reasonable alternative oral therapy for methicillin-susceptible S aureus or culture-negative AHO in pediatric patients, particularly when a less frequent dosing schedule is desired. Future study with a larger sample size is warranted.

News (Medical) associated with Cefadroxil

17 Jun 2024

·www.biospace.com

Hemogenyx Pharmaceuticals PLC Announces Operations Update - June 17, 2024

Operations Update LONDON, UNITED KINGDOM / ACCESSWIRE / June 17, 2024 / Hemogenyx Pharmaceuticals plc (LSE: HEMO), the clinical stage biopharmaceutical group developing treatments for cancers and viral diseases, is pleased to provide an update on its ongoing activities and progress. 1. HEMO-CAR-T Clinical Trials Progress: Additional Clinical Trial Site: The Company has added an additional prestigious US medical center to its list of clinical trial sites. This will enhance the scope and expedite the timeline for the implementation of clinical trials. Clinical Site Setup: The setup of clinical sites at the University of Pennsylvania ("PENN") and the new medical centre is underway. This multi-step process involves thorough internal reviews by the science review committee and the internal review board of both clinical sites, as well as budget negotiations and logistics planning. The Company continues to work with Prevail Infoworks, a contract research organization ("CRO"), to manage and oversee the planning for the clinical trials. Expansion into Pediatric Indications: Pediatric AML and ALL: The Company is seeking to expand the HEMO-CAR-T indication to include pediatric acute myeloid leukemia ("AML") and a subset of pediatric acute lymphoblastic leukemia ("ALL") patients. An amendment to the clinical protocol to include pediatric AML is currently under review by third party experts. If approved, the Company will seek to implement the clinical trials for pediatric AML at the newly established clinical site. This area is of particular concern, and there is an urgent need for effective treatments for these conditions, which the Company believes HEMO-CAR-T will be able to provide. 2. Chimeric Bait Receptor ("CBR") Platform The Company's CBR platform is an advanced immunotherapy designed to reprogram or redirect innate immune cells, such as macrophages, to prevent and combat infections from both existing and emerging viral threats, as well as to eliminate specific types of cancer. Development and Testing: CBR Constructs: Scientists at Hemogenyx Pharmaceuticals are developing and testing multiple CBR constructs to identify the best candidates for targeting rare cancers such as epithelial ovarian carcinoma. Selected candidates will undergo rigorous testing to advance them to investigational new drug (IND) enabling studies. mRNA-Based Delivery of CBR: Intranasal Delivery for Viral Infections: The Company continues to develop mRNA-based delivery of CBRs for treating airborne viral infections via intranasal administration. Recent improvements in the stability of mRNA-based CBRs are expected to enhance the effectiveness of this treatment. 3. CDX - Bispecific Antibody IND-Enabling Studies: Progress: The Company is advancing IND-enabling studies for CDX, a bispecific antibody designed for treating relapsed and/or refractory AML, a subset of ALL, and for conditioning in bone marrow transplants. Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals, commented: "We are excited about the progress we are making across our various programs. The addition of a world-renowned medical center to our HEMO-CAR-T clinical trial sites marks a significant step forward in our mission to develop life-saving therapies. Our expansion into pediatric indications for HEMO-CAR-T highlights our commitment to addressing unmet medical needs in both adult and pediatric populations. "Furthermore, our advancements in the CBR platform and the development of mRNA-based delivery systems for treating airborne viral infections demonstrate our innovative approach to tackling complex diseases. The progress in our CDX bispecific antibody program also underscores our dedication to bringing effective treatments to patients with relapsed or refractory AML and other severe conditions. "We are diligently pursuing non-dilutive financing options to support these initiatives and remain focused on translating our scientific discoveries into clinical success. We look forward to updating our shareholders and the market as we continue to make strides in our development programs." Market Abuse Regulation (MAR) Disclosure Certain information contained in this announcement would have been inside information for the purposes of Article 7 of Regulation No 596/2014 (as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018) until the release of this announcement. Enquiries: Hemogenyx Pharmaceuticals plc Dr Vladislav Sandler, Chief Executive Officer & Co-Founder headquarters@hemogenyx.com Peter Redmond, Director peter.redmond@hemogenyx.com SP Angel Corporate Finance LLP Tel: +44 (0)20 3470 0470 Matthew Johnson, Vadim Alexandre, Adam Cowl Peterhouse Capital Limited Tel: +44 (0)20 7469 0930 Lucy Williams, Duncan Vasey, Charles Goodfellow About Hemogenyx Pharmaceuticals plc Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City at its state-of-the-art research facility. The Company is a clinical-stage biopharmaceutical group developing new medicines and treatments for life-threatening diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as a platform technology that it uses as an engine for novel product development. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit . SOURCE: Hemogenyx Pharmaceuticals PLC View the original press release on accesswire.com

ImmunotherapyClinical Study

12 Jun 2024

·www.biospace.com

Foundation Medicine Announces Partnership with Repare Therapeutics to Provide Genomic Profiling Services to Support Clinical Trials and to Develop Companion Diagnostic for Lunresertib

BOSTON--(BUSINESS WIRE)-- Foundation Medicine, Inc., today announced that it has formed a collaboration with Repare Therapeutics, a leading clinical-stage precision oncology company, to provide prospective genomic profiling to patients in Repare’s ongoing Phase I/Ib MYTHIC study (NCT04855656) of lunresertib alone or in combinations in genomically-defined patient populations. The companies are also exploring opportunities to develop FoundationOne®CDx, a tissue-based comprehensive genomic profiling test, as a companion diagnostic for the lunresertib program. Lunresertib is a first-in-class, selective and potent oral small molecule inhibitor of PKMYT1, a cancer target Repare discovered and identified as synthetic lethal with CCNE1 amplification, FBXW7 and PPP2R1A alterations in solid tumors. Lunresertib is being evaluated alone and in combinations across several studies in the United States, Canada, European Union and United Kingdom. Repare has presented positive initial Phase 1 data, including compelling safety and anti-tumor activity, demonstrating proof of concept for lunresertib alone and in combination with camonsertib, a potential best-in-class ATR inhibitor developed by Repare and in Phase 1/2 development. Using a tissue sample, the U.S. Food and Drug Administration-approved FoundationOne CDx test analyzes more than 300 cancer-related genes for genomic alterations in a patient’s tumor. The test currently has over 35 companion diagnostic indications. Foundation Medicine is the global leader in companion diagnostic approvals with approximately 60% of all U.S. companion diagnostic approvals for next generation sequencing testing. “High-quality companion diagnostics are critical to inform treatment decisions, and they are especially important for detecting complex biomarkers in patients without any therapeutic options,” said Troy Schurr, Chief Biopharma Business Officer at Foundation Medicine. “We’re proud to partner with Repare Therapeutics as they work to advance this potential first-in-class therapy for patients with high unmet need.” Foundation Medicine® and FoundationOne® are registered trademarks of Foundation Medicine, Inc. About Foundation Medicine: Your Essential Partner in Cancer Care Foundation Medicine is a pioneer in molecular profiling for cancer, working to shape the future of clinical care and research. We collaborate with a broad range of partners across the cancer community and strive to set the standard for quality, scientific excellence, and regulatory leadership. Our deep understanding of cancer biology helps physicians make informed treatment decisions for their patients and empowers researchers to develop new medicines. Every day, we are driven to help our partners find answers and take action, enabling more people around the world to benefit from precision cancer care. For more information, please visit us on and follow us on X and LinkedIn. About FoundationOne®CDx FoundationOne®CDx is a next-generation sequencing based in vitro diagnostic device for detection of substitutions, insertion and deletion alterations (indels), and copy number alterations (CNAs) in 324 genes and select gene rearrangements, as well as genomic signatures including microsatellite instability (MSI) and tumor mutational burden (TMB) using DNA isolated from formalin-fixed, paraffin-embedded (FFPE) tumor tissue specimens. FoundationOne CDx is for prescription use only and is intended as a companion diagnostic to identify patients who may benefit from treatment with certain targeted therapies in accordance with their approved therapeutic product labeling. Additionally, FoundationOne CDx is intended to provide tumor mutation profiling to be used by qualified health care professionals in accordance with professional guidelines in oncology for patients with solid malignant neoplasms. Use of the test does not guarantee a patient will be matched to a treatment. A negative result does not rule out the presence of an alteration. Some patients may require a biopsy. For a full list of targeted therapies for which FoundationOne CDx is indicated as a companion diagnostic, please visit . View source version on businesswire.com: Contacts Foundation Medicine: Danielle Johns, 845-304-7408 newsroom@foundationmedicine.com Source: Foundation Medicine View this news release online at:

Clinical ResultPhase 1

04 Jun 2024

·www.biospace.com

Guardant Health introduces new Guardant360 TissueNext test with nearly 500 biomarkers to identify more treatment options for patients with advanced cancer

Upgraded gene panel on tissue genomic profiling test covers 498 biomarkers, including guideline-recommended genes Operational improvements streamline workflow and shorten time to results Upgraded test covered by Medicare for comprehensive genomic profiling of all advanced solid tumors PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced the launch of a new version of its Guardant360 TissueNext test that expands the number of genes it identifies in a tumor tissue sample to 498. These genes, or cancer biomarkers, enable oncologists to identify the targeted therapies or treatment strategies that are most effective for patients with advanced cancer. In addition to the panel expansion, Guardant has improved the test’s operational workflow for a faster turnaround time. The new Guardant360 TissueNext test will be covered for Medicare fee-for-service patients with advanced solid tumor cancers as a standalone service, based on coverage conveyed by Palmetto GBA, a Medicare administrative contractor for the Molecular Diagnostics Services program (MolDX®), under the existing local coverage determination. “The launch of the new Guardant360 TissueNext test is another step forward in our mission to conquer cancer with data,” said Helmy Eltouky, Guardant Health chairman and co-CEO. “In addition to identifying guideline-recommended biomarkers, the upgraded test now provides more comprehensive gene coverage, so oncologists can make better informed decisions about the optimal treatment strategy for their patients with advanced cancer and help improve their outcomes.” Guardant360 TissueNext identifies clinically relevant actionable biomarkers in tumor tissue to help oncologists select patients with advanced cancer who may benefit from biomarker-informed treatment. Results are provided in less than two weeks. The test, which first received Medicare coverage in March 2022, is part of Guardant’s comprehensive portfolio of blood- and tissue-based genomic profiling tests, including Guardant360 CDx, the first liquid biopsy test approved by the FDA for comprehensive genomic profiling of all solid tumors. The Guardant360 TissueNext test can be ordered alone or in combination with Guardant360 CDx to support guideline-recommended complementary liquid and tissue genomic profiling testing for advanced breast and lung cancer. About Guardant Health Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the best treatment for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook. Forward-Looking Statements This news release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health’s liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health’s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this news release include those discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2023, and in its other reports filed with or furnished to the Securities and Exchange Commission thereafter. The forward-looking statements in this news release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health’s views as of any date subsequent to the date of this press release. View source version on businesswire.com: Contacts Investor Contact: Zarak Khurshid investors@guardanthealth.com Source: Guardant Health, Inc. View this news release online at:

100 Deals associated with Cefadroxil

External Link

KEGG	Wiki	ATC	Drug Bank
-	Cefadroxil	J01DB05	DB01140

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Group a Streptococcal Pharyngitis	US	Warner Chilcott, Inc.	12 Sep 1980
Pharyngitis	US	Warner Chilcott, Inc.	06 Aug 1980
Skin and skin structure infections	US	Warner Chilcott, Inc.	06 Aug 1980
Tonsillitis	US	Warner Chilcott, Inc.	06 Aug 1980
Urinary Tract Infections	US	Warner Chilcott, Inc.	06 Aug 1980
Bacterial Infections	US	Warner Chilcott, Inc.	17 Feb 1978

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02446496 (CTgov)	Phase 4	Urinary Tract Infections	24	cefadroxil (Treatment A-cefadroxil 1 gm)	lizewiyxdx(xtngvzjyvs) = rajcwxuhts cznwkewlze (lmbmgioqoi, jzhpkudljx - ouhyubwtxb) View more	-	25 Apr 2017
				cefadroxil (Treatment B-cefadroxil 1 gm)	lizewiyxdx(xtngvzjyvs) = conjovvwyy cznwkewlze (lmbmgioqoi, hdszauvznb - yeluuehmhw) View more
NCT00834275 (CTgov)	Phase 1	-	26	Cefadroxil (Cefadroxil (Test))	ouiazfmqin(pyhoxrkuuq) = cftvqkeder fdhuetshiq (mkoxxcbzxf, otsanpoirk - jkvoyzitsu) View more	-	21 Jul 2009
				Duricef (Duricef® (Reference))	ouiazfmqin(pyhoxrkuuq) = dhfcjnnqqs fdhuetshiq (mkoxxcbzxf, zvtojzaxje - rigfqqjhyt) View more
NCT00835081 (CTgov)	Phase 1	-	26	Cefadroxil (Cefadroxil (Test))	jplzcqzyhb(hmpwafyffd) = aaahmssnny tcisuwaqoc (pdmswzemwt, iczbchjekz - npakbwnoff) View more	-	21 Jul 2009
				Duricef (Duricef® (Reference))	jplzcqzyhb(hmpwafyffd) = rumvxuvsqh tcisuwaqoc (pdmswzemwt, npdzxkoqki - eljoesoske) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis